{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:35:11Z","timestamp":1790717711272,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"State Key Program of National Natural Science Foundation of China","award":["81230027"],"award-info":[{"award-number":["81230027"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81070959"],"award-info":[{"award-number":["81070959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Key Project of Shanghai","award":["11411950300"],"award-info":[{"award-number":["11411950300"]}]},{"name":"Technology Support Project of Shanghai","award":["14140903300"],"award-info":[{"award-number":["14140903300"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jns.2014.08.010","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T06:35:19Z","timestamp":1407998119000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics"],"prefix":"10.1016","volume":"346","author":[{"given":"De-Sheng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Tai","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-2461","authenticated-orcid":false,"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2014.08.010_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48\u201349","author":"Gomez-Puerta","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jns.2014.08.010_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (aps)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jns.2014.08.010_bb0015","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2014.08.010_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic Antiphospholipid Syndrome Registry Project G. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.jns.2014.08.010_bb0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.287.6398.1021","article-title":"Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant","volume":"287","author":"Boey","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jns.2014.08.010_bb0030","article-title":"On behalf of the Euro-Phospholipid Project G. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","author":"Cervera","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jns.2014.08.010_bb0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","article-title":"Risk factors for arterial thrombosis in antiphospholipid syndrome","volume":"133","author":"Matyja-Bednarczyk","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jns.2014.08.010_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/10446670410001670526","article-title":"Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model","volume":"11","author":"Ziporen","year":"2004","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jns.2014.08.010_bb0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11926-013-0405-4","article-title":"Management of recurrent thrombosis in antiphospholipid syndrome","volume":"16","author":"Nalli","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jns.2014.08.010_bb0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jns.2014.08.010_bb0055","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1742-1241.2007.01478.x","article-title":"Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine","volume":"61","author":"Muscal","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jns.2014.08.010_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0961203312437810","article-title":"Aps action\u2013antiphospholipid syndrome alliance for clinical trials and international networking","volume":"21","author":"Erkan","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jns.2014.08.010_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0032-1304720","article-title":"Intensity and duration of anticoagulation therapy in antiphospholipid syndrome","volume":"38","author":"Les","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jns.2014.08.010_bb0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (apt) and anti-phosphatidylserine\/prothrombin (aps\/pt) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","author":"Sciascia","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jns.2014.08.010_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"British Committee for Standards in H. Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jns.2014.08.010_bb0080","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Euro-Phospholipid Project G: antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2014.08.010_bb0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0032-1313565","article-title":"The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management","volume":"38","author":"Favaloro","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jns.2014.08.010_bb0090","first-page":"630","article-title":"Neurological manifestations of the antiphospholipid syndrome","volume":"124","author":"Suarez","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jns.2014.08.010_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0961203312446974","article-title":"Antiphospholipid syndrome in northwest Italy (aps piedmont cohort): demographic features, risk factors, clinical and laboratory profile","volume":"21","author":"Bertero","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jns.2014.08.010_bb0100","first-page":"172","article-title":"Neurological manifestations in patients with antiphospholipid syndrome","volume":"12","author":"Etemadifar","year":"2013","journal-title":"Iran J Neurol"},{"key":"10.1016\/j.jns.2014.08.010_bb0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.20452\/pamw.2025","article-title":"Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand?","volume":"123","author":"Marchetti","year":"2013","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.jns.2014.08.010_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1751-553X.2012.01414.x","article-title":"Recent developments in our understanding of the antiphospholipid syndrome","volume":"34","author":"De Groot","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jns.2014.08.010_bb0115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.thromres.2013.07.023","article-title":"From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome","volume":"132","author":"Du","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jns.2014.08.010_bb0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pathophys.2010.04.010","article-title":"Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome","volume":"18","author":"Erkan","year":"2011","journal-title":"Pathophysiology"},{"key":"10.1016\/j.jns.2014.08.010_bb0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/keh408","article-title":"Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients","volume":"44","author":"Gomez-Puerta","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jns.2014.08.010_bb0130","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1001\/archinte.166.20.2278","article-title":"Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings","volume":"166","author":"Tektonidou","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jns.2014.08.010_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11926-011-0223-5","article-title":"The management of stroke in antiphospholipid syndrome","volume":"14","author":"Panichpisal","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jns.2014.08.010_bb0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5812\/nephropathol.10112","article-title":"The NF-kappaB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome","volume":"2","author":"Nishimura","year":"2013","journal-title":"J Nephropathol"},{"key":"10.1016\/j.jns.2014.08.010_bb0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaut.2010.06.015","article-title":"A novel mechanism of thrombosis in antiphospholipid antibody syndrome","volume":"35","author":"Vlachoyiannopoulos","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jns.2014.08.010_bb0150","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1365-2362.2012.02697.x","article-title":"Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome","volume":"42","author":"Oku","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jns.2014.08.010_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.berh.2012.01.006","article-title":"Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'","volume":"26","author":"Taraborelli","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jns.2014.08.010_bb0160","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/0961203309354541","article-title":"Peripheral neuropathy in patients with primary antiphospholipid (Hughes') syndrome","volume":"19","author":"Santos","year":"2010","journal-title":"Lupus"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2014.08.010_bb0165","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1179\/102453312X13336169156654","article-title":"Bleeding in the antiphospholipid syndrome","volume":"17","author":"Forastiero","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.jns.2014.08.010_bb0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"Lopez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jns.2014.08.010_bb0175","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11926-011-0222-6","article-title":"Potential use of statins in the treatment of antiphospholipid syndrome","volume":"14","author":"Lopez-Pedrera","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jns.2014.08.010_bb0180","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jns.2014.08.010_bb0185","first-page":"409","article-title":"Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin","volume":"30","author":"Sciascia","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jns.2014.08.010_bb0190","first-page":"877","article-title":"Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy","volume":"31","author":"Tenti","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14005413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14005413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:36:21Z","timestamp":1746336981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14005413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0022510X14005413"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.08.010","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}